The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status

Gynecologic Oncology

Volumn 143, Issue 3, 2016, Pages 628-635

  Shafrir, Amy L ^a,b   Rice, Megan S ^b,c   Gupta, Mamta ^d   Terry, Kathryn L ^a,b   Rosner, Bernard A ^a,b   Tamimi, Rulla M ^a,b   Hecht, Jonathan L ^d   Tworoger, Shelley S ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR; ESTROGEN RECEPTOR ALPHA, HUMAN;

ADULT; AGE; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCTION; TISSUE MICROARRAY; UTERINE TUBE LIGATION; ADENOCARCINOMA, CLEAR CELL; AGED; CANCER STAGING; CARCINOMA, ENDOMETRIOID; CASE CONTROL STUDY; ESTROGEN THERAPY; MENARCHE; MENOPAUSE; METABOLISM; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PARITY; PATHOLOGY; REPRODUCTIVE HISTORY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR; UNITED STATES; UTERINE TUBE STERILIZATION;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGE FACTORS; AGED; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MENARCHE; MENOPAUSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PARITY; POSTMENOPAUSE; RECEPTORS, PROGESTERONE; REPRODUCTIVE HISTORY; STERILIZATION, TUBAL; TIME FACTORS; TISSUE ARRAY ANALYSIS; UNITED STATES;

EID: 84997673970     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.09.024     Document Type: Article

References (40)

1. [1] Shih, I.M., Kurman, R.J., Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 164 (2004), 1511–1518.
2. [2] Kurman, R.J., Shih, I.M., Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 27 (2008), 151–160.
3. [3] Tothill, R.W., Tinker, A.V., George, J., Brown, R., Fox, S.B., Lade, S., Johnson, D.S., Trivett, M.K., Etemadmoghadam, D., Locandro, B., Traficante, N., Fereday, S., Hung, J.A., Chiew, Y.E., Haviv, I., Australian Ovarian Cancer Study, G., Gertig, D., DeFazio, A., Bowtell, D.D., Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14 (2008), 5198–5208.
4. [4] Karst, A.M., Drapkin, R., Ovarian cancer pathogenesis: a model in evolution. J. Oncol. 2010, 2010, 932371.
5. [5] Gates, M.A., Rosner, B.A., Hecht, J.L., Tworoger, S.S., Risk factors for epithelial ovarian cancer by histologic subtype. Am. J. Epidemiol. 171 (2009), 45–53.
6. [6] Tung, K.H., Reproductive factors and epithelial ovarian cancer risk by histologic type:a multiethnic case-control study. Am. J. Epidemiol. 158 (2003), 629–638.
7. [7] Yang, H.P., Trabert, B., Murphy, M.A., Sherman, M.E., Sampson, J.N., Brinton, L.A., Hartge, P., Hollenbeck, A., Park, Y., Wentzensen, N., Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study. Int. J. Cancer 131 (2012), 938–948.
8. [8] Kotsopoulos, J., Terry, K.L., Poole, E.M., Rosner, B., Murphy, M.A., Hecht, J.L., Crum, C.P., Missmer, S.A., Cramer, D.W., Tworoger, S.S., Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin. Int. J. Cancer 133 (2013), 730–739.
9. [9] Poole, E.M., Merritt, M.A., Jordan, S.J., Yang, H.P., Hankinson, S.E., Park, Y., Rosner, B., Webb, P.M., Cramer, D.W., Wentzensen, N., Terry, K.L., Tworoger, S.S., Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer Epidemiol. Biomark. Prev. 22 (2013), 429–437.
10. [10] Reiner, A., Neumeister, B., Spona, J., Reiner, G., Schemper, M., Jakesz, R., Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 50 (1990), 7057–7061.
11. [11] Colditz, G.A., Rosner, B.A., Chen, W.Y., Holmes, M.D., Hankinson, S.E., Risk factors for breast cancer according to estrogen and progesterone receptor status. J. Natl. Cancer Inst. 96 (2004), 218–228.
12. [12] Ma, H., Bernstein, L., Pike, M.C., Ursin, G., Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res., 8, 2006, R43.
13. [13] Hecht, J.L., Kotsopoulos, J., Hankinson, S.E., Tworoger, S.S., Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses’ health study. Cancer Epidemiol. Biomark. Prev. 18 (2009), 1624–1630.
14. [14] Stampfer, M.J., Willett, W.C., Speizer, F.E., Dysert, D.C., Lipnick, R., Rosner, B., Hennekens, C.H., Test of the National Death Index. Am. J. Epidemiol. 119 (1984), 837–839.
15. [15] Harris, H.R., Cramer, D.W., Vitonis, A.F., DePari, M., Terry, K.L., Folate, vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian cancer risk. Int. J. Cancer 131 (2012), E518–E529.
16. [16] Terry, K.L., De Vivo, I., Titus-Ernstoff, L., Sluss, P.M., Cramer, D.W., Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am. J. Epidemiol. 161 (2005), 442–451.
17. [17] Hecht, J.L., Kotsopoulos, J., Gates, M.A., Hankinson, S.E., Tworoger, S.S., Validation of tissue microarray technology in ovarian cancer: results from the Nurses’ health study. Cancer Epidemiol. Biomark. Prev. 17 (2008), 3043–3050.
18. [18] Silverberg, S.G., Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. 19 (2000), 7–15.
19. [19] Merritt, M.A., De Pari, M., Vitonis, A.F., Titus, L.J., Cramer, D.W., Terry, K.L., Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum. Reprod. 28 (2013), 1406–1417.
20. [20] H, M.E., H, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., Fitzgibbons, P.L., Francis, G., Goldstein, N.S., Hayes, M., Hicks, D.G., Lester, S., Love, R., Mangu, P.B., McShane, L., Miller, K., Osborne, C.K., Paik, S., Perlmutter, J., Rhodes, A., Sasano, H., Schwartz, J.N., Sweep, F.C., Taube, S., Torlakovic, E.E., Valenstein, P., Viale, G., Visscher, D., Wheeler, T., Williams, R.B., Wittliff, J.L., Wolff, A.C., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28 (2010), 2784–2795.
21. [21] Hefti, M.M., Hu, R., Knoblauch, N.W., Collins, L.C., Haibe-Kains, B., Tamimi, R.M., Beck, A.H., Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res., 15, 2013, R68.
22. [22] Glynn, R.J., Rosner, B., Methods to evaluate risks for composite end points and their individual components. J. Clin. Epidemiol. 57 (2004), 113–122.
23. [23] Jun, H.J., Austin, S.B., Wylie, S.A., Corliss, H.L., Jackson, B., Spiegelman, D., Pazaris, M.J., Wright, R.J., The mediating effect of childhood abuse in sexual orientation diparities in tobacco and alcohol use during adolescence: results from the Nurses’ health study II. Cancer Causes Control 21 (2010), 1817–1828.
24. [24] Sylvia, M.T., Kumar, S., Dasari, P., The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J. Pathol. Microbiol. 55 (2012), 33–37.
25. [25] Harding, M., Cowan, S., Hole, D., Cassidy, L., Kitchener, H., Davis, J., Leake, R., Estrogen and progesterone receptors in ovarian cancer. Cancer 65 (1990), 486–491.
26. [26] Fujimura, M., Hidaka, T., Kataoka, K., Yamakawa, Y., Akada, S., Teranishi, A., Saito, S., Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am. J. Surg. Pathol. 25 (2001), 667–672.
27. [27] Vang, R., Whitaker, B.P., Farhood, A.I., Silva, E.G., Ro, J.Y., Deavers, M.T., Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int. J. Gynecol. Pathol. 20 (2001), 252–259.
28. [28] Hogdall, E.V., Christensen, L., Hogdall, C.K., Blaakaer, J., Gayther, S., Jacobs, I.J., Christensen, I.J., Kjaer, S.K., Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the ‘MALOVA’ ovarian cancer study. Oncol. Rep. 18 (2007), 1051–1059.
29. [29] Rosner, B., Glynn, R.J., Tamimi, R.M., Chen, W.Y., Colditz, G.A., Willett, W.C., Hankinson, S.E., Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am. J. Epidemiol. 178 (2013), 296–308.
30. [30] Huang, W.Y., Newman, B., Millikan, R.C., Schell, M.J., Hulka, B.S., Moorman, P.G., Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am. J. Epidemiol. 151 (2000), 703–714.
31. [31] Nardulli, A.M., Greene, G.L., O'Malley, B.W., Katzenellenbogen, B.S., Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology 122 (1988), 935–944.
32. [32] Network, T.C.G.A., Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70.
33. [33] Network, C.G.A.R., Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
34. [34] Seal, M.D., Chia, S.K., What is the difference between triple-negative and basal breast cancers?. Cancer J. 16 (2010), 12–16.
35. [35] Lau, K.M., Mok, S.C., Ho, S.M., Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 5722–5727.
36. [36] Spillman, M.A., Manning, N.G., Dye, W.W., Sartorius, C.A., Post, M.D., Harrell, J.C., Jacobsen, B.M., Horwitz, K.B., Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res. 70 (2010), 8927–8936.
37. [37] Mukherjee, K., Syed, V., Ho, S.M., Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene 24 (2005), 4388–4400.
38. [38] Sieh, W., Salvador, S., McGuire, V., Weber, R.P., Terry, K.L., Rossing, M.A., Risch, H., Wu, A.H., Webb, P.M., Moysich, K., Doherty, J.A., Felberg, A., Miller, D., Jordan, S.J., Cancer ACSO, Group AOCS, Goodman, M.T., Lurie, G., Chang-Claude, J., Rudolph, A., Kjaer, S.K., Jensen, A., Hogdall, E., Bandera, E.V., Olson, S.H., King, M.G., Rodriguez-Rodriguez, L., Kiemeney, L.A., Marees, T., Massuger, L.F., van Altena, A.M., Ness, R.B., Cramer, D.W., Pike, M.C., Pearce, C.L., Berchuck, A., Schildkraut, J.M., Whittemore, A.S., Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int. J. Epidemiol. 42 (2013), 579–589.
39. [39] Cibula, D., Widschwendter, M., Zikan, M., Dusek, L., Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet. Gynecol. Scand. 90 (2011), 559–563.
40. [40] Akahane, T., Sekizawa, A., Okuda, T., Kushima, M., Saito, H., Okai, T., Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer. Int. J. Gynecol. Pathol. 24 (2005), 369–376.